Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2023-12-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
长城证券股份有限公司关于浙江泰林生物技术股份有限公司使用募集资金向全资子公司增资的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Changcheng Securities regarding Zhejiang Tailin Biotechnology Co., Ltd.'s use of raised funds to increase capital in its wholly-owned subsidiary. It references regulatory approvals, fundraising details, use of proceeds, board resolutions, and compliance with securities regulations. The document is not a full financial report but a regulatory compliance and verification statement related to fundraising and capital use. It does not contain comprehensive financial statements or earnings data but focuses on the use of raised funds and related approvals. This fits the category of a Regulatory Filing (RNS) as it is a compliance and verification document related to fundraising and capital use, not a full report or announcement of voting results or capital changes themselves.
2023-12-12 Chinese
第三届董事会第二十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting, including decisions on capital increase to a subsidiary and asset purchase participation. It details the meeting date, attendance, and voting results. It references other announcements for detailed information but does not contain financial statements or detailed financial data itself. The content fits the category of Board/Management Information (MANG) as it relates to board meeting decisions and management actions rather than financial reports or other filings.
2023-12-12 Chinese
关于使用募集资金向全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the use of raised funds to increase capital in its wholly-owned subsidiary. It details the approval of the board meeting, the amount of capital increase, the use of funds raised from previous public offerings and convertible bonds, and compliance with regulatory requirements. The document includes financial data of the subsidiary but does not contain comprehensive financial statements or detailed financial performance analysis typical of an annual or interim report. It is primarily an announcement about the use of fundraising proceeds and capital allocation to a subsidiary, which fits the category of Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive information about capital use, not just a brief notice or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is CAP with high confidence.
2023-12-12 Chinese
关于全资子公司拟参与竞拍购买资产的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a transaction where the company's wholly-owned subsidiary plans to participate in an asset purchase auction. It includes details about the transaction, counterparties, asset information, and risk disclosures. It is a corporate announcement about a financing or capital investment activity, not a full financial report, earnings release, or management discussion. The document length is short (1314 characters) and it is not a report publication or certification. The content fits best under Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes through asset acquisition.
2023-12-12 Chinese
“泰林转债”2023年第一次债券持有人会议决议公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of the resolution from a bondholders' meeting for a convertible bond issued by Zhejiang Tailin Biotechnology Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There are no financial statements or detailed financial data presented, and the document is relatively short (1299 characters). It is not a full report but an official announcement of meeting decisions and voting outcomes related to bondholders. This fits best under the category of Capital/Financing Update (CAP), as it relates to bondholder meetings and decisions affecting the company's financing instruments.
2023-12-12 Chinese
上海市锦天城律师事务所关于浙江泰林生物技术股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2023 second extraordinary general meeting (EGM) of Zhejiang Tailin Biotechnology Co., Ltd. It details the legality of the meeting's convocation, attendance, agenda, and voting results. The document does not contain financial statements or detailed financial data but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcement (DVA), as it officially reports the voting outcomes and related procedural confirmations of a shareholder meeting.
2023-12-12 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.